ACLX News and Press, Arcellx Inc. From 05/25/24

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-15 08:00:04 ET Benjamin Burnett from Stifel Nicolaus issued a price target of $83.00 for ACLX on 2024-05-15 06:37:00. The adjusted price target was set to $83.00. At the time of the announcement, ACLX was trading at $50.62. The overall price target consensus is a...

2024-05-14 11:24:32 ET More on BioNTech, Moderna, etc. BioNTech SE 2024 Q1 - Results - Earnings Call Presentation BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks Moderna announces del...

2024-05-10 07:10:29 ET More on Arcellx Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset Seeking Alpha’s Quant Rating on Arcellx Historical earnings data for Arcellx Financial information for Arcellx Read the ...

2024-05-09 17:13:21 ET More on Gilead Sciences, Arcellx Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gi...

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...

-- The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody -- -- Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as th...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. ...

2024-05-02 10:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund rose 15.33%, outperforming the broade...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...